121 related articles for article (PubMed ID: 10570511)
1. [Skin reactions to interferon alpha in a series of 92 patients with multiple sclerosis].
Fortuño Y; Marcoval J; Gallego I; Moreno A; Arbizu T; Peyrí J
Med Clin (Barc); 1999 Oct; 113(12):447-8. PubMed ID: 10570511
[TBL] [Abstract][Full Text] [Related]
2. [Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b].
Río J; Marzo ME; Tintoré M; Borrás C; Montalbán X
Neurologia; 1998 Nov; 13(9):422-6. PubMed ID: 9883016
[TBL] [Abstract][Full Text] [Related]
3. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis.
Szilasiová J; Gdovinová Z; Jautová J; Baloghová J; Ficová M; Bohus P
Clin Neuropharmacol; 2009; 32(5):301-3. PubMed ID: 19820436
[TBL] [Abstract][Full Text] [Related]
5. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
Ball NJ; Cowan BJ; Hashimoto SA
J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
7. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
8. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.
Ozden MG; Erel A; Erdem O; Oztas MO
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):112-3. PubMed ID: 15649205
[TBL] [Abstract][Full Text] [Related]
9. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
10. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
Bayas A; Gold R
J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
[TBL] [Abstract][Full Text] [Related]
11. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
12. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
13. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
15. Response to beta interferon 1b among Saudi patients with multiple sclerosis.
Kargwell H; Yaqub BA; Al-Deeb SM
Saudi Med J; 2003 Jan; 24(1):44-8. PubMed ID: 12590273
[TBL] [Abstract][Full Text] [Related]
16. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
Hernandez-Perez MA;
Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum.
Elgart GW; Sheremata W; Ahn YS
J Am Acad Dermatol; 1997 Oct; 37(4):553-8. PubMed ID: 9344192
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
19. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient.
Gono T; Matsuda M; Shimojima Y; Kaneko K; Murata H; Ikeda S
J Clin Neurosci; 2007 Oct; 14(10):997-1000. PubMed ID: 17669654
[TBL] [Abstract][Full Text] [Related]
20. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
